



Medicine: clostridium botulinum neurotoxin type A (brand name: Xeomin®) for chronic sialorrhoea due to neurological disorders

Merz Pharma UK Ltd

What is clostridium botulinum neurotoxin type A for?

Clostridium botulinum neurotoxin type A is used for the treatment of chronic sialorrhoea (excessive drooling). Sialorrhoea is a feature of many neurological conditions (including Parkinson's, motor neurone disease, stroke or cerebral palsy). Sialorrhoea can increase the risk of choking and causes skin problems, infections, sleep disturbance and difficulties in eating and speaking and can lead to embarrassment and loss of dignity, and distress for both patients and carers.

How does clostridium botulinum neurotoxin type A work?

Clostridium botulinum neurotoxin type A reduces the amount of saliva that is produced by blocking nerve cell signals to the salivary glands.

What has SMC said?

SMC has accepted clostridium botulinum neurotoxin type A for the treatment of chronic sialorrhoea due to neurological conditions in adults.



Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.

- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration of the evidence, SMC was able to accept clostridium neurotoxin type A as a possible treatment within NHSScotland.

What does SMC's decision mean for me?

If your healthcare professional thinks that clostridium botulinum neurotoxin type A for use as described above is the right medicine for you, you should be able to have your treatment on the NHS in Scotland. For further information see:

Medicines in Scotland: What's the right treatment for me?

www.healthcareimprovementscotland.org/medicinesbooklet.aspx



More information

The organisations below can provide more information and support for people with neurological conditions and their families. SMC is not responsible for the content of any information provided by external organisations.

Ataxia UK



<http://www.ataxia.org.uk>



0845 644 0606

MND Scotland



<http://www.mndscotland.org.uk>



0141 332 3903

Neurological Alliance of Scotland



<http://www.scottishneurological.org.uk>

Parkinson's UK Scotland



<http://www.parkinsons.org.uk/scotland>



0808 800 0303

You can find out more about clostridium botulinum neurotoxin type A (Xeomin) in the patient information leaflet (PIL) on the electronic medicines compendium (EMC) web-site.



<https://www.medicines.org.uk/emc>

Date advice published: 11 November 2019

SMC No: (SMC2212)